TB Elimination and Laboratory Cooperative Agreement Funding

Background

CDC is continued its 40-year approach of funding priority activities in TB programs through cooperative agreements to complement TB prevention and control activities and laboratory services at state and local levels to reduce TB morbidity and mortality. The goal of this five-year cooperative agreement (CDC-RFA-PS-25-0003) is to prevent TB transmission and prevent progression from latent TB infection to active TB disease.

Officials in health departments are responsible for TB control and prevention activities and laboratory services under the statutes and regulations of states, cities, or territories. This funding complements those efforts. It is not meant to replace or reduce state and local investment in priority activities and responsibilities such as diagnosing and treating TB, providing inpatient care, tracing contacts, finding, and treating latent TB infection, and managing health department clinics

Funding by category

CDC TB Cooperative Agreement funding consists of three parts:

1. Prevention and Control (P&C)
2. Human Resource Development (HRD)
3. Public Health Laboratory Strengthening

CDC distributes TB Cooperative Agreement funds according to a case-based formula for P&C and HRD, and a workload-based funding formula for the laboratory. This formula is based on years of experience and collaboration with public health partners.

Project priorities

Strategies and activities

• Diagnosis/treatment of persons with TB disease and persons with latent TB infection;
• Examination of immigrants and refugees who have an overseas B classification for TB;
• Targeted testing for, and treatment of latent TB infection;
• Program planning, evaluation, and improvement;
• Epidemiologic surveillance and response;
• Human resource development and partnership activities; and
• Public health laboratory strengthening.

Expected outcomes

Expected outcomes include but are not limited to:

• Decreases in TB incidence;
• Increases in patients completing treatment within 12 months;
• Increases in HIV and drug susceptibility testing in TB cases;
• Increases in latent TB infection testing and treatment completion rates of those recommended for treatment;
• Increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data;
• Improvement in turnaround times for specimen receipt and laboratory testing and
• Implementation of TB elimination plans.

Recipients

Award recipients include state, local and territorial health departments, or their Bona Fide Agents.

This includes the 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. Also included are local health departments serving the following areas: Chicago, IL; Houston, TX, Los Angeles, CA; New York, NY; Philadelphia, PA; San Diego, CA; and San Francisco, CA.

Resources